NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 165 filers reported holding NEKTAR THERAPEUTICS in Q4 2014. The put-call ratio across all filers is 0.54 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $9,001,000 | -3.8% | 733,599 | +34.6% | 0.01% | -16.7% |
| Q3 2016 | $9,361,000 | +14.7% | 544,904 | -5.0% | 0.01% | +20.0% |
| Q2 2016 | $8,160,000 | -9.2% | 573,469 | -12.2% | 0.01% | -16.7% |
| Q1 2016 | $8,983,000 | -16.3% | 653,281 | +2.6% | 0.01% | -14.3% |
| Q4 2015 | $10,731,000 | +55.8% | 636,866 | +1.3% | 0.01% | +55.6% |
| Q3 2015 | $6,888,000 | -4.8% | 628,436 | +8.7% | 0.01% | 0.0% |
| Q2 2015 | $7,235,000 | +75.9% | 578,311 | +54.7% | 0.01% | +80.0% |
| Q1 2015 | $4,113,000 | -28.7% | 373,919 | +0.5% | 0.01% | -37.5% |
| Q4 2014 | $5,769,000 | +28.8% | 372,193 | +0.3% | 0.01% | +33.3% |
| Q3 2014 | $4,479,000 | -5.3% | 371,110 | +0.6% | 0.01% | 0.0% |
| Q2 2014 | $4,728,000 | +5.4% | 368,788 | -0.3% | 0.01% | -14.3% |
| Q1 2014 | $4,485,000 | +16.0% | 370,060 | +8.7% | 0.01% | +16.7% |
| Q4 2013 | $3,865,000 | +6.2% | 340,493 | -2.3% | 0.01% | 0.0% |
| Q3 2013 | $3,641,000 | -5.9% | 348,631 | +4.0% | 0.01% | -14.3% |
| Q2 2013 | $3,871,000 | – | 335,190 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 2,000,000 | $67,200,000 | 3.35% |
| First Light Asset Management, LLC | 763,403 | $25,650,000 | 3.33% |
| BRIDGER MANAGEMENT, LLC | 1,238,489 | $41,613,000 | 3.29% |
| Rhenman & Partners Asset Management AB | 734,445 | $24,677,000 | 2.89% |
| BB BIOTECH AG | 2,020,676 | $67,895,000 | 1.71% |
| Gs Investments, Inc. | 54,200 | $1,821,120,000 | 1.43% |
| Artal Group S.A. | 900,000 | $30,240,000 | 1.24% |
| Cormorant Asset Management, LP | 500,000 | $16,800,000 | 1.14% |
| TOBAM | 640,547 | $21,522,000 | 1.09% |
| Bellevue Group AG | 430,026 | $14,449,000 | 0.80% |